


Human Journals

Research Article

August 2016 Vol.:4, Issue:2

© All rights are reserved by Rajashekar Vadlakonda et al.

RP-HPLC Method Development and Validation for the Estimation of Armodafinil and Valsartan



IJSRM
INTERNATIONAL JOURNAL OF SCIENCE AND RESEARCH METHODOLOGY
An Official Publication of Human Journals



HUMAN

Rajashekar Vadlakonda*, Upender Rao Eslawath¹

**Department of Pharmaceutical Chemistry, Vikas College of Pharmacy, Jangaon, Warangal, Telangana-506167*

¹ Department of Pharmaceutical Analysis, Vikas College of Pharmacy, Jangaon, Warangal, Telangana-506167, India.

Submission: 29 July 2016
Accepted: 7 August 2016
Published: 25 August 2016



HUMAN JOURNALS

www.ijsrm.humanjournals.com

Keywords: Armodafinil, Valsartan, Validation, RSD, Regression, Precision, Accuracy

ABSTRACT

The current manuscript deals with development and validation of RP-HPLC method for estimation of Armodafinil and Valsartan. The proposed method is simple, selective, reproducible, sensitive and accurate with good precision. Some of the methods were proved to be superior to most of the reported methods. All these proposed methods for estimation of selected drugs such as Armodafinil and Valsartan were successfully applied either in bulk or pharmaceutical formulations. The precision of the method was estimated by analyzing sample solutions. Six multiple samples (from a homogeneous lot) were analysed and content of Valsartan is determined as mg/ tab of the tablet. The RSD of the content was found to be well within the limits (i.e. %RSD<2%). The linearity was investigated in the range of 1 to 200 mcg/ml using six different concentrations. The areas obtained at 250 nm for Valsartan were fitted to a straight line by the method of least squares. Linear regression analysis for Valsartan was calculated and was found to be 0.9999. Accuracy was investigated in the concentration range of 80-120% of the standard concentration for Valsartan. The percentage recovery values obtained lie within the standard limit of 98 % to 102%. The proposed method can be used as alternative method to the reported ones for the routine determination of selected drugs under the study in bulk and pharmaceutical dosage forms.

INTRODUCTION

Chromatography is a separation process that is achieved by distributing the components of a mixture between two phases, a stationary phase, and a mobile phase. Those components held preferentially in the stationary phase are retained longer in the system than those that are distributed selectively in the mobile phase. Consequently, solutes are eluted from the system as local concentrations in the mobile phase in the order of their increasing distribution coefficients with respect to the stationary phase; ipso facto, a separation is achieved. The technique was originally developed by Russian botanist M.S.Tswett in 1903. The definite breakthrough for liquid chromatography of low molecular weight compounds was the introduction of chemically modified small diameter particles (3 to 10 μm) e.g., octadecyl groups bound to silica in the late 1960's.

High-performance liquid chromatography (HPLC) is a form of column chromatography used frequently in biochemistry and analytical chemistry. It is also sometimes referred to as High-Pressure Liquid Chromatography. The name "HPLC" originally referred to the fact that high pressure is required to generate the flow required for liquid chromatography in packed columns. In the beginning, instrument components only had the capability of generating pressures of 500psi (35 bars). The early 1970's saw a tremendous leap in technology. These new "HPLC" instruments could develop up to 6,000psi (400 bar) of pressure, and included improved detectors and columns. HPLC really began to take hold in the mid to late 1970's. With continued advances in performance, the name was changed to High Performance Liquid Chromatography (HPLC).

MATERIALS AND METHODS

LIST OF INSTRUMENTS USED

Table 1: List of Instruments

| Sr.No | Instruments/Equipments/Apparatus |
|-------|---|
| 1. 1. | HPLC-Waters Separation Module 2695 with Waters 2696 PDA |
| 2. 2. | UV-Visible Spectrophotometer (Agilent 8543). |
| 3. 3. | Electronic Balance (Mettler toledo) |
| 4. 4. | Ultra Sonicator (Enertech) |
| 5. 6. | Symmetry -C18 (250 X 4.6mm, 5 μm) column |
| 6. 7. | Zorbax -C18 (150 X 4.6mm, 5 μ) column |
| 7. 8. | x-Terra-RP18, 4.6×150mm, 5μm |
| 8. 9. | pH Analyzer (744 Metrohm) |

LIST OF CHEMICALS, REAGENTS AND STANDARDS USED:

Table 2: List of Chemicals, Reagents and Standards

| Sr.No | Chemicals / Reagents / Standards | Grade | Specification |
|-------|----------------------------------|-------|---------------|
| 1. | Sodium dihydrogen phosphate | AR | 99.0% |
| 2. | Methanol | HPLC | 99.8% |
| 3. | Acetonitrile | HPLC | 99.8% |
| 4. | Water | NA | NA |
| 5. | Armodafinil working standard | AR | 99.0% |
| 6. | Armodafinil sample | NA | 99.92 (w/v) |
| 7. | Valsartan working standard | NA | 99.96 (w/w) |
| 8. | Valsartan sample | NA | 99.93 (w/v) |
| 13. | Hydrogen peroxide | NA | NA |
| 14. | Sodium Hydroxide | NA | NA |
| 15. | Hydrochloric Acid | NA | NA |
| 16. | Orthophosphoric Acid | NA | NA |

OPTIMIZED CHROMATOGRAPHIC CONDITIONS:

Table 3: Optimized Chromatographic Conditions

| Parameters | Method |
|-------------------------------------|---|
| Stationary phase (column) | Symmetry C18 (250 x 4.6 x 5 μ) |
| Mobile Phase | Buffer (0.02M NaH ₂ PO ₄ PH- 2.5): ACN (58: 42) |
| Flow rate (ml/min) | 1.0 |
| Run time (minutes) | 20 |
| Column temperature ($^{\circ}$ C) | Ambient |
| Volume of injection loop (μ l) | 10 |
| Detection wavelength (nm) | 250 |
| Drugs RT (min) | 9.349 |

ANALYSIS:

Preparation of Mobile Phase:

Preparation of 0.02 M buffer:

Accurately weighed 3.01gm of Sodium dihydrogen orthophosphate and dissolved in one liter of millipore water and pH adjusted to 5.8. Adjust the prepared Buffer at pH 5.8.

Mobile phase preparation/Diluent:

A mixture of Buffer (58%) and 42% of Acetonitrile was prepared after filtration.

Preparation of Standard Solution:

Accurately about 5 mg of the Valsartan working standard was weighed and transferred into 50 ml clean, dry standard volumetric flask. To this about 20 ml of diluent was added and then it was kept in an ultrasonic bath to dissolve. The volume is made up to the mark with the diluent and mixed well. This yielded a standard stock solution with concentration 100 ppm of Valsartan. This working standard solution was analyzed using the HPLC conditions mentioned above.

Buffer Preparation: Accurately weigh and transfer about 2.72gm of potassium dihydrogen orthophosphate in 1000 ml of purified water and mix. Adjust the solution pH to 4.0 with dilute orthophosphoric acid. Filter the solution through 0.45 μ membrane filter.

Mobile phase preparation: Mixture of buffer and Acetonitrile in the ratio of 650: 350 was prepared after filter and degassed.

Diluent preparation: use mobile phase as diluent.

STANDARD PREPARATION: (for Armodafinil tablets 50mg and 250 mg)

Accurately weighed and transferred about 25mg of Armodafinil working standard into a 100 ml volumetric flask to it 60ml of methanol was added and mixture was sonicated to dissolve. Solution was cooled to room temperature and diluted with methanol. 5 ml of above solution was transferred to 25 ml of volumetric flask and diluted with diluent.

SAMPLE PREPARATION: (for Armodafinil tablets 50mg)

Accurately weighed and powdered 20 tablets and transferred, equivalent to 250mg of armodafinil into 250ml volumetric flask. 160 ml of methanol was added and sonicated for 45 minutes with occasional shaking. The mixture was cooled to room temperature and diluted with methanol, filtered through 0.45 μ m membrane filter. 5ml of above solution transferred to 100 ml volumetric flask and diluted with diluent.

Weigh and finely powder not fewer than 20 tablets. Transfer accurately weighed portion of the powder, equivalent to 250mg of Armodafinil into a 250 ml volumetric flask. Add about 160ml of methanol and sonicate for 45 minutes with occasional shakings. Cool the solution to room temperature and dilute to volume with methanol. Filter the solution through 0.45 μ m membrane filter. Transfer 5ml the above filter solution into a 100 ml volumetric flask. Dilute to volume with diluent.

SAMPLE PREAPARTION: (for Armodafinil tablets 250mg)

Accurately weighed and powdered 20 tablets and transferred, equivalent to 1250 mg of armodafinil into 250ml volumetric flask. 160 ml of methanol was added and sonicated for 45

minutes with occasional shaking. The mixture was cooled to room temperature and diluted with methanol, filtered through 0.45 μ m membrane filter. 2 ml of above solution transferred to 100 ml volumetric flask and diluted with diluent.

Weigh and finely powder not fewer than 20 tablets. Transfer accurately weighed portion of the powder, equivalent to 1250mg of Armodafinil into a 250 ml volumetric flask. Add about 160ml of methanol and sonicate for 45 minutes with occasional shakings. Cool the solution to room temperature and dilute to volume with methanol. Filter the solution through 0.45 μ m membrane filter. Transfer 2ml the above filtered solution into a 200 ml volumetric flask. Dilute to volume with diluent.

STANDARD PREPARATION: (for Armodafinil tablets 150mg)

Accurately weighed and transferred about 24mg of Armodafinil working standard into a 100 ml volumetric flask and added 60ml of methanol and sonicated to dissolve. Cooled the solution to room temperature and diluted to volume with methanol. Transferred 5 ml of the above solution into a 25 ml volumetric flask and diluted to volume with diluent.

SAMPLE PREPARATION: (for Armodafinil tablets 150mg)

Accurately weighed and powdered 20 tablets and transferred, equivalent to 750mg of armodafinil into 250ml volumetric flask. 160 ml of methanol was added and sonicated for 45 minutes with occasional shaking. The mixture was cooled to room temperature and diluted with methanol, filtered through 0.45 μ m membrane filter. 4ml of above solution transferred to 100 ml volumetric flask and diluted with diluent.

Weigh and finely powder not fewer than 20 tablets. Transfer accurately weighed portion of the powder, equivalent to 750mg of Armodafinil into a 250 ml volumetric flask. Add about 160ml of methanol and sonicate for 45 minutes with occasional shakings. Cool the solution to room temperature and dilute to volume with methanol. Filter the solution through 0.45 μ m membrane filter. Transfer 4ml the above filtered solution into a 250 ml volumetric flask. Dilute to volume with diluent.

RESULTS

SYSTEM SUITABILITY

Diluent Chromatogram







Figure 1: Chromatogram of Diluent





| S. No. | Sample Name | Vial | Inj | Name | RT | Area | USP Tailing | USP Plate Count |
|----------|---------------------------------------|------|-----|-------------|-------|---------|-------------|-----------------|
| 1 | Armodafinil_Assay_Standard(50-250 mg) | 50 | 1 | Armodafinil | 3.391 | 1603465 | 1.16 | 5224 |
| 2 | Armodafinil_Assay_Standard(50-250 mg) | 50 | 2 | Armodafinil | 3.394 | 1601522 | 1.15 | 5107 |
| 3 | Armodafinil_Assay_Standard(50-250 mg) | 50 | 3 | Armodafinil | 3.397 | 1599865 | 1.15 | 5111 |
| 4 | Armodafinil_Assay_Standard(50-250 mg) | 50 | 4 | Armodafinil | 3.398 | 1605703 | 1.15 | 5121 |
| 5 | Armodafinil_Assay_Standard(50-250 mg) | 50 | 5 | Armodafinil | 3.408 | 1600061 | 1.16 | 5163 |
| 6 | Armodafinil_Assay_Standard(50-250 mg) | 50 | 6 | Armodafinil | 3.394 | 1601102 | 1.15 | 5096 |
| Mean | | | | | 3.397 | 1601953 | 1.15 | 5136.8 |
| Std.Dev. | | | | | 0.006 | 2244.94 | | |
| %RSD | | | | | 0.2 | 0.14 | | |

Armodafinil Assay Calculations

| Armodafinil Formulations (mg) | Test Area | Test Wt. | Avg. Wt. | Label Amount(mg) | % of result | Statistical analysis |
|-------------------------------|-----------|----------|----------|------------------|-------------|--|
| 250 | 1672308 | 3251.9 | 625.9 | 250 | 100.6 | AVG. =100.65 SD =0.070711 %RSD=0.07025 |
| | 1672937 | 3429.7 | 625.9 | 250 | 100.7 | |
| 150 | 1570716 | 1891.5 | 376.6 | 150 | 100.4 | AVG. =99.6 SD =1.1313 %RSD=1.1359 |
| | 1546276 | 1892.4 | 376.6 | 150 | 98.8 | |
| 50 | 1574525 | 618.5 | 125.1 | 50 | 99.5 | AVG. =99.2 SD =0.4242 %RSD=0.4276 |
| | 1564664 | 618.7 | 125.1 | 50 | 98.9 | |

VALSARTAN

SYSTEM SUITABILITY


| Concentration | Injection | Area | Retention time |
|--|----------------|-----------------------|----------------|
| 100 ppm | Injection-1 | 1757046 | 9.335 |
| | Injection-2 | 1756314 | 9.342 |
| | Injection-3 | 1756437 | 9.41 |
| | Injection-4 | 1760266 | 9.398 |
| | Injection-5 | 1765267 | 9.387 |
| | Injection-6 | 1773636 | 9.385 |
| STATISTICAL ANALYSIS | Avg | 1761494 | 9.376167 |
| | Std | 6860.933 | 0.03059 |
| | %Rsd | 0.389495 | 0.326256 |
| | TAILING FACTOR | 0.9 | |
| | PLATE COUNT | 7.3 * 10 ³ | |
| Acceptance Criteria: RSD should be not more than 2.0 % | | | |

METHOD PRECISION

| Concentration | Sample no | Injection 1 | Injection 2 | Average |
|--|-----------|-------------|-------------|------------|
| 100 ppm | Sample-1 | 1755394 | 1756443 | 1755918 |
| | Sample-2 | 1772277 | 1772237 | 1772257 |
| | Sample-3 | 1728206 | 1771459 | 1749832 |
| | Sample-4 | 1786190 | 1786276 | 1786233 |
| | Sample-5 | 1719461 | 1721105 | 1720283 |
| | Sample-6 | 1811502 | 1817307 | 1814404 |
| STATISTICAL ANALYSIS | | | Average | 1766487.83 |
| | | | Std | 32382.5221 |
| | | | %Rsd | 1.83315852 |
| Acceptance Criteria: RSD should be not more than 2.0 % | | | | |

LINEARITY

| Sample | Concentration | Inj 1 | Inj 2 | Avg |
|--------|---------------|---------|---------|---------|
| 1 | 1 | 20813 | 20918 | 20755 |
| 2 | 5 | 93149 | 96272 | 94287 |
| 3 | 50 | 904888 | 896324 | 897863 |
| 4 | 100 | 1768520 | 1764689 | 1767713 |
| 5 | 150 | 2701998 | 2709753 | 2709660 |
| 6 | 200 | 3572932 | 3577105 | 3576763 |



ACCURACY

| Sample ID | Concentration ($\mu\text{g/ml}$) | | %Recovery of | Statistical Analysis | |
|--|------------------------------------|-------------|--------------|----------------------|--------|
| | Pure drug | Formulation | Pure drug | | |
| S ₁ : 80 % | 160 | 200 | 99.98 | Mean | 99.88 |
| S ₂ : 80 % | 160 | 200 | 99.82 | SD | 0.085 |
| S ₃ : 80 % | 160 | 200 | 99.85 | % RSD | 0.085 |
| S ₄ : 100 % | 200 | 200 | 99.76 | Mean | 99.34 |
| S ₅ : 100 % | 200 | 200 | 99.51 | SD | 0.5316 |
| S ₆ : 100 % | 200 | 200 | 98.74 | % RSD | 0.5351 |
| S ₇ : 120 % | 240 | 200 | 99.73 | Mean | 99.73 |
| S ₈ : 120 % | 240 | 200 | 99.94 | SD | 0.215 |
| S ₉ : 120 % | 240 | 200 | 99.51 | % RSD | 0.2156 |
| Acceptance Criteria: RSD should be not more than 2.0 % | | | | | |

DISCUSSION

The %RSD value, plate count and tailing factor results were found to be well within limits as per the ICH guidelines. The precision of the method was estimated by analysing sample solutions. Six multiple samples (from a homogeneous lot) were analysed and content of Valsartan is determined as mg/ tab of the tablet. The RSD of the content was found to be well within the limits (i.e. %RSD<2%). The linearity was investigated in the range of 1 to 200 $\mu\text{gm/ml}$ using six different concentrations. The areas obtained at 250 nm for Valsartan were fitted to a straight line by the method of least squares. Linear regression analysis for Valsartan was calculated and was found to be 0.9999. Accuracy was investigated in the concentration range of 80-120% of the standard concentration for Valsartan. The percentage recovery values obtained lie within the standard limit of 98 % to 102%.

CONCLUSION

The proposed method was found to be simple, precise, accurate and rapid for determination of Valsartan from pure and its dosage forms. The mobile phase is simple to prepare and economical. The sample recoveries in all formulations were in good agreement with their

respective label claims and they suggested non – interference of formulation excipients in the estimation. Hence, the method can be easily and conveniently adopted for routine analysis of Valsartan in dosage forms and can also be used for dissolution or similar studies.

The proposed method is simple, selective, reproducible, sensitive and accurate with good precision. Some of the methods were proved to be superior to most of the reported methods. All these proposed methods for estimation of selected drugs such as Armodafinil and Valsartan were successfully applied either in bulk or pharmaceutical formulations.

The proposed methods can be used as alternative method to the reported ones for the routine determination of selected drugs under the study in bulk and pharmaceutical dosage forms.

ACKNOWLEDGEMENTS

I humbly present this work to the eternal almighty. Indeed my final work is done with the help of primitive persons at heart. So it is my bounded duty to promulgate them individually.

I wish to extend my sincere thanks **Sri. L. Venkateshwarlu**, Principal, Vikas College of Pharmacy, Jangaon for his valuable ideas which made me to finish this work.

ABBREVIATIONS

| | |
|------|---|
| HPLC | High performance Liquid Chromatography |
| NMT | Not More Than |
| % | Percent |
| AUC | Area Under Curve |
| LC | Liquid Chromatography |
| PDA | Photodiode Array |
| ICH | International Conference on Harmonization |
| GR | General reagent |
| C18 | Octadecyl |
| UV | Ultraviolet |
| ml | Milliliter |
| Min | Minute |

| | |
|------|------------------------------|
| MeOH | Methanol |
| μl | Micro-Liter |
| μ | Micron |
| μg | Microgram |
| N | Normality |
| M | Molar |
| ppm | Parts per million |
| nm | Nanometer |
| RSD | Relative Standard Deviation |
| Fig | Figure |
| cv | Coefficient of variation |
| HIV | Human Immunodeficiency Virus |

REFERENCES

1. Robert D. Braun, Introduction to Instrumental Analysis, 1st Edition, Mc Graw Hill Book Company, 1987.
2. Lloyd R. Snyder, Joseph J. Krikland and Joseph © L. Glajch, Practical HPLC method development.
3. B.K. Sharma, Instrumental methods of Chemical Analysis, 10th Edition, Goal Publishing House.
4. Remington, The Science And Practice of Pharmacy, 20th edition, page No 624-630.
5. Vogel's Textbook of Quantitative Chemical Analysis, sixth edition, page no 726-728
6. Douglas A. Skoog, F. James Holler, Timothy A. Nieman, Principle of instrumental analysis, fifth edition, page no. 380-400.
7. William Kemp, Organic Spectroscopy, Third edition, page no. 50-55
8. Standy Lindsay, HPLC by open learning, John Wiley and London.
9. Analytical Chemistry, May 1, 1996, (68) 304A-309A Copyright 1996 by the American Chemical Society HPLC Systems. Analytical Development/Assay Validation hand Book of Generic Development. 1996.